{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:01:59Z","timestamp":1791838919288,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Janus kinase (JAK) inhibitors, biologics, and phosphodiesterase\u20104 (PDE\u20104) inhibitors are recent therapies for alopecia areata (AA)\u2014albeit, knowledge gaps exist for these agents' relative efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We determined the relative efficacy and safety of monotherapy with the aforementioned agents in adults with AA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The literature was systematically searched; we used data from randomized trials that investigated the agents' efficacy\u2014as per Severity of Alopecia Tool (SALT) scores. Bayesian network meta\u2010analyses were used to determine relative efficacy and safety. Effect modification was determined using a generalized linear model on aggregate data; evidence quality was evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Based on the surface under the cumulative ranking curve estimates obtained from multiple efficacy endpoints, regimens with the highest likelihood of achieving percent reduction in SALT scores, as well as a minimum 90%, 75% or 50% reduction in SALT scores are (in alphabetical order) baricitinib 4\u2009mg once daily (QD), brepocitinib 60\/30\u2009mg QD, deuruxolitinib (CTP\u2010543) 12\u2009mg twice daily (BID), ritlecitinib 200\/50\u2009mg QD, ruxolitinib 20\u2009mg BID and tofacitinib 5\u2009mg BID. In contrast, dupilumab subcutaneous injections administered weekly and apremilast 30\u2009mg BID were less likely to be effective. Discontinuation due to any adverse event was the least likely with oral JAK inhibitors, and more likely with dupilumab and apremilast.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results support the conduct of high\u2010quality comparative trials to determine whether JAK inhibitors are more effective and safer than PDE4 inhibitors.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.15903","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T04:39:16Z","timestamp":1689395956000},"page":"2553-2559","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta\u2010analyses of clinical trials"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"},{"name":"Division of Dermatology, Department of Medicine University of Toronto School of Medicine  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Bamimore","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine University of Toronto School of Medicine  Toronto Ontario Canada"},{"name":"Division of Dermatology Women's College Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"Fredric Brandt Endowed Professor of Dermatology University of Miami  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.874677"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/S12016-021-08883-0"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5743"},{"key":"e_1_2_11_5_1","unstructured":"RStudio Team.RStudio: integrated development environment for R.2022. Published Online.http:\/\/www.rstudio.com\/"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000494613"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.15071"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.050"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.045"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2110343"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00403-018-1876-Y"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.016"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099682"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1428"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950450"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489"},{"key":"e_1_2_11_18_1","unstructured":"U.S. Food And Drug Administration.Prescribing information for the use of OLUMIANT (Baricitinib) tablets.2022. Published. Accessed June 17 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s007lbl.pdf"},{"key":"e_1_2_11_19_1","unstructured":"European Medicines Agency.Overview of Olumiant (baricitinib).2022. Published. Accessed March 31 2023.https:\/\/www.ema.europa.eu\/en\/documents\/overview\/olumiant\u2010epar\u2010medicine\u2010overview_en\u20100.pdf"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18883"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-022-03170-7"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.048"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S334727"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.09.051"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00764-w"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac059"},{"key":"e_1_2_11_29_1","unstructured":"U.S. Food and Drug Administration.Patient\u2010focused drug development initiative \u2013 alopecia areata. Published 2018.https:\/\/www.fda.gov\/media\/112100\/download"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T10:30:09Z","timestamp":1691749809000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.15903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/jocd.15903"],"URL":"https:\/\/doi.org\/10.1111\/jocd.15903","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]},"assertion":[{"value":"2023-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}